MwanzoSUNPHARMA • NSE
add
Sun Pharmaceutical Industries Ltd
Bei iliyotangulia
₹ 1,609.70
Bei za siku
₹ 1,603.10 - ₹ 1,622.50
Bei za mwaka
₹ 1,553.05 - ₹ 1,960.35
Thamani ya kampuni katika soko
3.88T INR
Wastani wa hisa zilizouzwa
2.58M
Uwiano wa bei na mapato
37.23
Mgao wa faida
0.99%
Ubadilishanaji wa msingi
NSE
Habari za soko
Investor's Business Daily
dakika 7 zilizopita
Fed Looms With Market At Highs; 7 Stocks Near Buy Points
0.59%
0.37%
7.36%
0.62%
Fedha
Taarifa ya Mapato
Mapato
Mapato halisi
| (INR) | Jun 2025info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato | 138.51B | 9.47% |
Matumizi ya uendeshaji wa biashara | 76.65B | 9.90% |
Mapato halisi | 22.79B | -19.64% |
Kiwango cha faida halisi | 16.45 | -26.60% |
Mapato kwa kila hisa | 11.98 | 1.48% |
EBITDA | 39.63B | 10.32% |
Asilimia ya kodi ya mapato | 27.51% | — |
Taarifa ya Hali ya Kifedha
Jumla ya mali
Jumla ya dhima
| (INR) | Jun 2025info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Uwekezaji wa pesa taslimu na vipindi vifupi | 261.23B | 36.84% |
Jumla ya mali | — | — |
Jumla ya dhima | — | — |
Jumla ya hisa | 724.86B | — |
hisa zilizosalia | 2.40B | — |
Uwiano wa bei na thamani | 5.35 | — |
Faida inayotokana na mali | — | — |
Faida inayotokana mtaji | 11.26% | — |
Mtiririko wa pesa
Mabadiliko halisi ya pesa taslimu
| (INR) | Jun 2025info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato halisi | 22.79B | -19.64% |
Pesa kutokana na shughuli | — | — |
Pesa kutokana na uwekezaji | — | — |
Pesa kutokana na ufadhili | — | — |
Mabadiliko halisi ya pesa taslimu | — | — |
Mtiririko huru wa pesa | — | — |
Kuhusu
Sun Pharmaceutical Industries Limited is an Indian multinational pharmaceutical company headquartered in Mumbai. It manufactures and sells pharmaceutical formulations and active pharmaceutical ingredients in more than 100 countries. It is the largest pharmaceutical company in India and the fourth largest specialty generic pharmaceutical company in the world.
Around 70% of Sun Pharma’s revenue is generated from international markets. The US and India are the largest markets, accounting for over 60% of the company's turnover. Manufacturing is across 43 locations in India, the US, Asia, Africa, Australia and Europe. The products cater to therapeutic segments covering psychiatry, anti-infectives, neurology, cardiology, diabetology, gastroenterology, ophthalmology, nephrology, urology, dermatology, gynaecology, respiratory, oncology, dental and nutritionals. Its active pharmaceutical products include baricitinib, brivaracetam, and dapaglifozin. Wikipedia
Ilianzishwa
1983
Makao Makuu
Tovuti
Wafanyakazi
43,000
